CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Rise in the adoption of the cancer profiling methods by oncologists
3.6.1.2. Increase in the use of biomarkers in cancer profiling
3.6.1.3. Increase in the demand for next-generation sequencing technique in cancer profiling
3.6.1.4. Rise in incidence of cancer across the globe
3.6.2. Restraints
3.6.2.1. High monetary investments in the development of biomarkers
3.6.2.2. Dearth of skilled professionals
3.6.3. Opportunities
3.6.3.1. Increasing demand for personalized medicine
CHAPTER 4 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. NEXT-GENERATION SEQUENCING (NGS)
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. POLYMERASE CHAIN REACTION (PCR)
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. IMMUNOHISTOCHEMISTRY (IHC)
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. IN SITU HYBRIDIZATION (ISH)
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.5.1. Fluorescence in Situ Hybridization (FISH)
4.5.1.1. Market Size & Forecast
4.5.2. Chromogenic in Situ Hybridization (CISH)
4.5.2.1. Market Size & Forecast
4.6. MICROARRAY
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
4.7. OTHER TECHNOLOGIES
4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast
CHAPTER 5 CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. GENOMICS
5.2.1. Market size and forecast
5.3. PROTEOMICS
5.3.1. Market size and forecast
5.4. EPIGENETICS
5.4.1. Market size and forecast
5.5. METABOLOMICS
5.5.1. Market size and forecast
CHAPTER 6 CANCER/TUMOR PROFILING MARKET, BY APPLICATION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. PERSONALIZED MEDICINE
6.2.1. Market size and forecast
6.3. DIAGNOSTICS
6.3.1. Market size and forecast
6.4. BIOMARKER DISCOVERY
6.4.1. Market size and forecast
6.5. PROGNOSTICS
6.5.1. Market size and forecast
6.6. RESEARCH APPLICATIONS
6.6.1. Market size and forecast
CHAPTER 7 CANCER/TUMOR PROFILING MARKET, BY GEOGRAPHY
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Mexico market size and forecast
7.2.3.3. Canada market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.3.1. UK market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. Germany market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. India market size and forecast
7.4.3.4. Australia market size and forecast
7.4.3.5. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.3.1. Brazil market size and forecast
7.5.3.2. Argentina market size and forecast
7.5.3.3. Turkey market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. QIAGEN N.V.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments
8.2. ROCHE MOLECULAR SYSTEMS INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Business performance
8.2.5. Key strategic moves and developments
8.3. ABBOTT LABORATORIES
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. ILLUMINA INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. NEOGENOMICS LABORATORIES
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments
8.6. HTG MOLECULAR DIAGNOSTIC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.6.5. Key strategic moves and developments
8.7. GENOMIC HEALTH INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. HOLOGIC GEN-PROBE
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.8.5. Key strategic moves and developments
8.9. BD BIOSCIENCES (BECKTON DICKINSON)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments
8.10. SIEMENS HEALTHINEERS
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
8.10.5. Key strategic moves and developments